IP
IndiaPulse

DELTACORP

Small Cap

Delta Corp Limited

Consumer

Delta Corp Limited operates in Gaming & Hospitality, within the Consumer sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹65.23
-0.20 · -0.31%
Quote09 Jun, 10:02 am
Fundamentals08 Jun 2026 · screener
Score08 Jun, 11:00 pm · v4.2-nightly
Tags02 May 2026
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Investable fundamentals, management trust is acceptable, price trend is neutral, and recent execution is weak.

Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
UNDERVALUED
64

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Mixed Trust
64

low confidence · 0/0 claims checked

Technical
Neutral
52

Timing lens: price trend and sector relative strength.

Result consistency
weak
29

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 31 Mar 2026

Bad · 0/100

Rev -12% YoY · PAT -90% YoY · margin compression

Filed 22 Apr 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹161 Cr-12.0%+0.6%
EBITDA₹28 Cr-31.7%+27.3%
Operating margin17.0%-500 bps+300 bps
PAT₹16 Cr-90.3%+14.3%
PAT margin9.9%-8022 bps+119 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business and thesis

Issuer presentation review pending

Delta Corp Limited operates in Gaming & Hospitality, within the Consumer sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Technical timing lens

Trend score and candlestick chart

52Neutral

SMA20 +6.2% / mo

Stock trend: 57
Sector RS: 45
Sector 3M: -0.7% vs Nifty +0.1%

Technical chart

DELTACORPweekly · 1Y-28.2%
Latest close ₹65.36 on 2026-06-09
Bar
+0.6%
RSI
46
MACD hist
-0.23
52W pos
37%
Hover for OHLC, volume, and indicators. Use range buttons above the chart to zoom.
₹46₹59₹71₹84₹9752H52L2025-062025-092025-122026-03Vol2025-062025-102026-012026-052026-06
Up bar
Down bar
Volume
Result date
SMA 50
RSI(14)

Technical trend read

Mixed signals

Signals are conflicting — long-term trend unclear. RSI 46. Wait for confirmation.

  • SMA20 rising (~5.8% over last month) — short-term momentum positive.
  • RSI(14) at 46 — rising, no extreme reading.
  • MACD below signal, histogram expanding negatively — bearish momentum building.
  • 31% off 52W high · 35% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Deep research

Valuation, score drivers, trust methodology, financials, and peers

Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.

64U-SCORE
Growth at Value

Fundamental score breakdown

UNDERVALUED
Valuation20/30
Growth19/25
Quality0/20
Balance Sheet12/15
Cash Flow8/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
64

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

64/100 · UNDERVALUED

Positive drivers

  • Piotroski is strong at 8/9.
  • Fair-value margin of safety is positive at 73.8%.
  • Balance sheet contributes 12/15 to the score.

Main drags

  • Quality is weaker at 0/20; verify the latest quarterly trend.
  • Valuation is weaker at 20/30; verify the latest quarterly trend.
  • Growth is weaker at 19/25; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
19.6
PB
0.8
EV/EBITDA
10.1
ROE
3.6%
ROCE
5.0%
FCF Yield
2.3%
Debt/Equity
0.0
MoS
+73.8%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 08 Jun 2026
v4.2-nightly
Final score
64
Previous: 64
Verdict
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+73.8%
Previous: +73.8%

Score history

12 stored score snapshots. Latest stored move: +0 points.

08 Jun 2026
v4.2-nightly
63
63
64
64
64
64
64
64
64
64
64
64

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Trust Score
64Mixed Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Mixed Trust: Claim history is still being built. It ranks around the 42nd percentile of the scored universe and 42nd percentile within Consumer. Main check: results consistency is weak at 29/100.

Healthy Trust Lite: Promoter pledge is zero. Key concern: 4 recent quarters had PAT decline worse than 25% YoY.

Computed 22 May 2026
trust-lite-v1
0 docs indexed · 0 concall links
Score band
Mixed Trust

Usable, but needs evidence. Treat guidance with a margin of safety.

Relative rank
42nd percentile

overall median 67 · Consumer: 42nd pctile, median 67 · Small: 47th pctile, median 65

Evidence depth
Financial-only

0 documents indexed, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Mixed Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
29
weak · quarterly consistency

Trust positives

  • Promoter pledge is zero.
  • FCF yield is positive at 2%.
  • 11 years of positive FCF.
  • Debt/equity is 0.02.

Trust risks

  • 4 recent quarters had PAT decline worse than 25% YoY.
  • ROCE is low at 5%.
  • ROE is low at 3.6%.
  • ROCE trend is -3.6%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Intrinsic value

Graham Number
₹77.69
+16.0% MoS
DCF Fair PE
78.0
DCF Fair Value
₹248.82
+73.8% MoS
PEG
0.45

Fundamentals

Valuation

P/E
19.60
P/B
0.78
EV/EBITDA
10.11
Market Cap
1751.00Cr

Profitability

ROE
3.64%
ROCE
5.02%
ROA
3.30%
Dividend Y
1.91%

Growth (CAGR)

Revenue 5Y
10.00%
EPS 5Y
44.00%
Revenue 3Y
-11.00%
EPS 3Y
-30.00%

Balance Sheet

Debt/Equity
0.02
Interest Coverage
21.83×
Altman Z
5.22
Book Value
84.10

Cash Flow

FCF Yield
2.28%
FCF Positive Y
11/5
OCF
135.00 Cr
EPS TTM
3.19

Shareholding

Promoter Hold
34.46%
Promoter Pledge
0.00%
Momentum 52W
34%

Financial History

Updated 9/6/2026

Revenue

₹ Cr
Latest: 52.5k-5.4% vs prev
073kMar 2026: 72.7kMar 2025: 61.9kMar 2024: 49.5kMar 2023: 55.5kMar 2022: 52.5kFY26FY25FY24FY23FY22

Net Profit

₹ Cr
No data

Return on Equity

%
No data
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.